NASDAQ · Biotechnology

Celularity Inc. (CELU) Stock

$0.75 +0.13% NASDAQ: CELU Healthcare

Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources.

Valuation

MetricValue
Price$0.75
Market Cap$21.74M
P/E Ratio-0.20
P/B Ratio-0.50
P/S Ratio0.82
EPS (TTM)$-3.59
52-Week High$4.31
52-Week Low$0.56
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE411.46%
ROA-85.45%
ROCE-230.74%
Gross Margin-225.93%
Operating Margin-225.93%
Net Margin-345.44%
Debt/Equity-1.07
Current Ratio0.15

Annual Financials (USD)

Metric20212022202320242025
Revenue$21.0M$18.0M$23.0M$54.0M$27.0M
Operating Profit$-109.0M$-26.0M$-192.0M$-38.0M$-61.0M
Net Profit$-100.0M$14.0M$-196.0M$-58.0M$-92.0M
EPS$-7.87$0.95$-11.02$-2.64$-3.59
Op Margin-511.2%-142.4%-844.4%-70.8%-230.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$414.0M$401.0M$144.0M$133.0M$107.0M
Total Liabilities$315.0M$202.0M$103.0M$124.0M$145.0M
Cash$37.0M$14.0M$0$1.0M$6.0M
Borrowings$31.0M$66.0M$65.0M$69.0M$41.0M

Latest News

Celularity Appoints Chief Operating Officer MT Newswires · Jun 26, 2026 Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies GlobeNewswire · Jun 4, 2026 Celularity Releases CEO Letter to Shareholders GlobeNewswire · Jun 3, 2026 Celularity Appoints Rick Gonzalez as Chief Commercial Officer GlobeNewswire · Jun 3, 2026 Celularity Receives Nasdaq Notice Regarding Form 10-Q GlobeNewswire · May 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-110.0M$-138.0M$-39.0M$-6.0M$-13.0M
Investing Cash Flow$-12.0M$-10.0M$-8.0M$0$0
Financing Cash Flow$98.0M$27.0M$7.0M$0$0
Net Cash Flow$-17.0M$-23.0M$-19.0M$1.0M$5.0M
Free Cash Flow$-116.0M$-143.0M$-43.0M$-7.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-0.71
FCF Yield-59.80%
Quick Ratio0.14
Interest Coverage-8.71
Return 1Y-68.55%
Return 3Y-84.34%
Return 5Y-99.24%

Ownership

Insiders Held37.18%
Institutions Held12.77%
Institutions Float Held20.34%
Institutional HolderSharesReport Date
C V STARR & CO INC764,0692026-03-31
Vanguard Capital Management LLC621,1052026-03-31
Geode Capital Management, LLC191,0762026-03-31
Blackrock Inc.127,5012026-03-31
Vanguard Fiduciary Trust Co79,8742026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVS $1.70 +0.59% -1.54 $33.45M 0.00%
ATNM $0.80 +1.32% -1.07 $25.02M 0.00%
BCABBioAtla, Inc. $3.40 +0.89% -0.08 $4.29M 0.00%
BTAIBioXcel Therapeutics, Inc. $0.87 +2.30% -0.13 $26.77M 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%

About Celularity Inc.

Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.

Celularity Inc. is led by CEO Robert Joseph Hariri, employs 120 people, headquartered in US, publicly traded since 2019.

Celularity Inc. (CELU) stock trades at $0.75 with a market capitalization of $21.74M. The stock is valued at a price-to-earnings (P/E) ratio of -0.20, price-to-book of -0.50, price-to-sales of 0.82. Over the past 52 weeks the stock has ranged between $0.56 and $4.31, and currently trades 82.6% below its 52-week high.

On profitability, Celularity Inc. generates a return on equity (ROE) of 411.46% — well above the market average, a sign of a high-quality business, return on capital employed of -230.74%, an operating margin of -225.93%, a net profit margin of -345.44%.

Official website: www.celularity.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides